Brain cancer is doubly difficult to treat as most
chemotherapeutics are cytotoxic and uptake to the tumor is poor due to the
blood-brain-barrier. Recently, researchers at Yantai University (China) used
PLGA-PEG-Mal (Polyvivo AI020) from PolySciTech (www.polyscitech.com)
to generate targeted nanoparticles for treating glioma. This research holds
promise for improved therapy of brain cancer. Read more: Hua, Hongchen, Xuemei
Zhang, Hongjie Mu, Qingqing Meng, Ying Jiang, Yiyun Wang, Xiaoyan Lu et al.
"RVG29-modified Docetaxel-loaded nanoparticles for brain-targeted glioma
therapy." International Journal of Pharmaceutics (2018). https://www.sciencedirect.com/science/article/pii/S0378517318301753
“Abstract: Gliomas are the most common malignant brain
tumor, but treatment is limited by the blood–brain barrier (BBB), especially
for chemotherapeutic drugs. Although some chemotherapy drugs can pass through
the BBB, many of these agents are toxic to normal brain tissue. To maximize
therapeutic effects, chemotherapeutic drugs must accumulate at the glioma site.
In this study, a specific ligand (the RVG29 peptide) that can combine with
acetylcholine receptors was conjugated to polyethylene glycol-modified
poly-(D,L-lactide-co-glycolide) (PEG-PLGA) to develop a targeted carrier;
preparation of the targeted docetaxel nanoparticles (DTX-NPs) was performed by
the nanoprecipitation method. The NPs were approximately 110 nm and had smooth
surfaces. Enzyme-linked immunoassay results showed that the amount of receptor
on the surface of glioma cells was 2.04-fold higher than that of nonmalignant
cells, which may promote accumulation of RVG29-modified NPs at the targeting
site. NPs showed targeting properties for glioma cells compared with the
non-targeting NPs in an in vitro cellular uptake test. Targeted NPs also showed
better BBB penetration in an in vitro model. In vivo tests indicated that
RVG29-PEG-PLGA-NPs could selectively accumulate in intracranial glioma tissue.
In conclusion, these results indicated that the RVG29-modified NPs have
potential efficacy for glioma therapy. Keywords: Brain-targeting; glioma;
RVG29; blood–brain barrier; Docetaxel”
-
BPCR conference (August 29, 2018 9AM - 4PM: Kurz Purdue Technology Center,
West Lafayette, IN) is a free, 1-day scientific networking conference hosted by
Akina, Inc. which focuses on research companies in the biotechnology,
pharmaceutical, medical, and broader life-science fields. See more at BPCRconference.com
No comments:
Post a Comment